Stocks · News reference
UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BrightSpring Health Services (BTSG) is rated a Strong Buy with strong momentum in Provider Services and expanding specialty pharmacy and infusion operations. However, the company faces near-term margin pressure from Inflation Reduction Act reimbursement cuts and execution risks from multiple integrations and geographic expansions through 2026.
Cooper Companies reported Q3 adjusted EPS of $1.15, beating estimates by 3.6%, but revenues of $1.066 billion missed expectations by 3.0%. CooperVision faced pressure from U.S. channel inventory reductions, while CooperSurgical showed resilience with 2% revenue growth. The stock fell 15.9% after-hours as management expects continued destocking headwinds in Q4, though underlying U.S. consumption remains healthy.
GE HealthCare Technologies has submitted its next-generation StarGuide GX digital SPECT/CT system for FDA 510(k) clearance following CE Mark approval in Europe. The system features dual-sided CZT detectors, NVIDIA RTX computing, and rapid collimator exchange, designed to support emerging radioligand therapies including alpha emitters like Actinium-225 and Lead-212. Despite the regulatory milestone, GEHC stock declined 3% following the announcement.